Lebrikizumab responses on the head and neck held to three years

Design

Post hoc analysis of phase 3 and targeted lebrikizumab trials

Population

Adolescents and adults with moderate-to-severe atopic dermatitis

Primary outcome

Head-and-neck EASI response and facial IGA

Effect

Head-and-neck EASI-75 maintained in 94.8% of week-16 responders at week 152

Head, neck and face eczema is hard to treat and weighs heavily on quality of life. This post hoc analysis pooled phase 3 lebrikizumab trials (ADvocate 1 and 2 with the ADjoin extension) and two targeted studies, in adolescents and adults with moderate-to-severe atopic dermatitis.

Among patients who had responded by week 16 and continued 250 mg every four weeks, 94.8% maintained head-and-neck EASI-75 at week 152, and 69.2% had a head-and-neck EASI of zero. In ADmirable, a study in skin of colour, 61% reached a facial IGA of 0 at week 24. In ADapt, in patients previously given dupilumab, 55% did.

The analysis is post hoc and restricted to early responders, which inflates long-term figures. The authors include company investigators.

For patients whose eczema concentrates on the face and neck, this is supportive evidence that a response to lebrikizumab, once achieved, tends to last.

• Most week-16 responders kept head-and-neck EASI-75 through about three years.
• Facial clearance was reported in skin of colour and after prior dupilumab.
• Figures apply to early responders only — non-responders at week 16 are excluded.
• Assess face and neck separately when judging response to a biologic.
• Ask about facial symptoms specifically; they drive quality of life out of proportion to area.

Why it matters

It addresses the body site where eczema most often stays visible after other areas clear.

Don't overread it

This post hoc analysis of early responders overstates what an unselected patient can expect.

The statistics, in plain English

Restricting to week-16 responders means these percentages describe how well responses last, not how many patients respond. A post hoc analysis was not planned in advance, so it is more prone to selective reporting.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.